Version in force 17 December 2022

Previous version, in force 1 March 2022 02008R1272-20220301 → this version, in force 17 December 2022 02008R1272-20221217

compared line by line: this provision is too large to compare word by word, so a marked line is a line that changed somewhere

ANNEX VI Harmonised classification and labelling for certain hazardous substances Part 1 of this Annex provides an introduction to the list of harmonised classification and labelling, including information listed for each entry and related classifications and hazard statements in Table 3. … 479 unchanged lines … H302 H318 H317 H410 005-007-00-2 boric acid; [1] boric acid; [2] 233-139-2 [1] H410 005-007-00-2 boric acid [1] boric acid [2] 233-139-2 [1] 234-343-4 [2] 10043-35-3 [1] 11113-50-1 [2] Repr. 1B H360FD GHS08 Dgr H360FD Repr.1B; H360FD: C ≥ 5,5 % 005-008-00-8 diboron trioxide; boric oxide 215-125-8 1303-86-2 Repr. 1B H360FD GHS08 Dgr H360FD Repr.1B; H360FD:C ≥ 3,1 % 005-009-00-3 tetrabutylammonium butyltriphenylborate 418-080-4 120307-06-4 Skin Sens. 1 Dgr H360FD 005-008-00-8 diboron trioxide 215-125-8 1303-86-2 Repr. 1B H360FD GHS08 Dgr H360FD 005-009-00-3 tetrabutylammonium butyltriphenylborate 418-080-4 120307-06-4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410 005-010-00-9 N, N-dimethylanilinium tetrakis(pentafluorophenyl)borate 422-050-6 118612-00-3 Carc. 2 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 H351 H302 H315 H318 GHS08 GHS05 GHS07 Dgr H351 H302 H315 H318 005-011-00-4 disodium tetraborate, anhydrous; boric acid, disodium salt; [1] tetraboron disodium heptaoxide, hydrate; [2] orthoboric acid, sodium salt [3] 215-540-4 [1] 235-541-3 [2] 237-560-2 [3] 1330-43-4 [1] 12267-73-1 [2] 13840-56-7 [3] Repr. 1B H360FD GHS08 Dgr H360FD Repr. 1B; H360FD: C ≥4,5 % 005-011-01-1 disodium tetraborate decahydrate; borax decahydrate 215-540-4 1303-96-4 Repr. 1B H360FD GHS08 Dgr H360FD Repr.1B; H360FD: C ≥ 8,5 % 005-011-02-9 disodium tetraborate pentahydrate; borax pentahydrate 215-540-4 12179-04-3 Repr. 1B H360FD GHS08 Dgr H360FD Repr.B; H360FD: C ≥ 6,5 % 005-012-00-X diethyl{4-[1,5,5-tris(4-diethylaminophenyl)penta-2,4-dienylidene]cyclohexa-2,5-dienylidene}ammonium butyltriphenylborate 418-070-1 141714-54-7 Skin Sens. 1 H318 005-011-00-4 tetraboron disodium heptaoxide, hydrate; [1] disodium tetraborate, anhydrous; [2] orthoboric acid, sodium salt [3] disodium tetraborate decahydrate [4] disodium tetraborate pentahydrate [5] 235-541-3 [1] 215-540-4 [2] 237-560-2 [3] 215-540-4 [4] 215-540-4 [5] 12267-73-1 [1] 1330-43-4 [2] 13840-56-7 [3] 1303-96-4 [4] 12179-04-3 [5] Repr. 1B H360FD GHS08 Dgr H360FD 005-012-00-X diethyl{4-[1,5,5-tris(4-diethylaminophenyl)penta-2,4-dienylidene]cyclohexa-2,5-dienylidene}ammonium butyltriphenylborate 418-070-1 141714-54-7 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 … 867 unchanged lines … 3,5-xylyl methylcarbamate — 2655-14-3 Acute Tox. 4 * H302 GHS07 Wng H302 006-068-00-8 diazomethane 206-382-7 334-88-3 Carc. 1B H350 GHS08 Dgr H350 006-069-00-3 thiophanate-methyl (ISO); 1,2-di-(3-methoxycarbonyl-2-thioureido)benzene 245-740-7 23564-05-8 Muta. 2 Acute Tox. 4 * dimethyl (1,2-phenylenedicarbamothioyl)biscarbamate; dimethyl 4,4′-(o-phenylene)bis(3-thioallophanate) 245-740-7 23564-05-8 Carc. 2 Muta. 2 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H341 Aquatic Chronic 1 H351 H341 H332 H317 H400 H410 GHS08 GHS07 GHS09 Wng H341 Wng H351 H341 H332 H317 H410 006-070-00-9 furmecyclox (ISO); H410 inhalation: ATE = 1,7 mg/l (dusts and mists) M = 10 M = 10 006-070-00-9 furmecyclox (ISO); N-cyclohexyl-N-methoxy-2,5-dimethyl-3-furamide 262-302-0 60568-05-0 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 … 33 unchanged lines … H373 ** H334 H317 H410 006-076-00-1 mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt — 8018-01-7 Repr. 2 H410 006-076-00-1 mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt — 8018-01-7 Carc. 2 Repr. 1B STOT RE 2 Skin Sens. 1 Aquatic Acute 1 H361d*** Aquatic Acute 1 Aquatic Chronic 1 H351 H360D H373 (thyroid, nervous system) H317 H400 GHS08 H400 H410 GHS08 GHS07 GHS09 Wng H361d*** Dgr H351 H360D H373 (thyroid, nervous system) H317 H400 M=10 006-077-00-7 maneb (ISO); H410 M = 10 M = 10 006-077-00-7 maneb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) 235-654-8 12427-38-2 Repr. 2 … 2,382 unchanged lines … H300 GHS06 Dgr H310 H300 015-113-00-0 tolclofos-methyl (ISO); O-(2,6-dichloro-p-tolyl)-O,O-dimethyl thiophosphate 260-515-3 57018-04-9 Skin Sens. 1 O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate 260-515-3 57018-04-9 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410 015-114-00-6 chlormephos (ISO); H410 M = 1 M = 1 015-114-00-6 chlormephos (ISO); S-chloromethyl O,O-diethyl phosphorodithioate 246-538-1 24934-91-6 Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 … 2,400 unchanged lines … H317 H410 028-007-00-4 trinickel disulfide; nickel subsulfide; [1] heazlewoodite [2] 234-829-6[1] -[2] 12035-72-2 [1] heazlewoodite [2] 234-829-6 [1] - [2] 12035-72-2 [1] 12035-71-1 [2] Carc. 1A Muta. 2 Acute Tox. 3 STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H350i H341 H331 H372** H317 H400 H410 GHS08 GHS07 GHS06 GHS09 Dgr H350i H341 H372** H317 H410 028-008-00-X nickel dihydroxide; [1] H331 H372** H317 H410 inhalation: ATE = 0,92 mg/l (dusts or mists) 028-008-00-X nickel dihydroxide; [1] nickel hydroxide [2] 235-008-5 [1] 234-348-1 [2] 12054-48-7 [1] 11113-74-9 [2] Carc. 1A … 1,191 unchanged lines … Dgr H332 H302 H318 H410 M = 100 029-003-00-5 naphthenic acids, copper salts; H410 inhalation: ATE = 3,34 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 100 M = 10 029-003-00-5 naphthenic acids, copper salts; copper naphthenate 215-657-0 1338-02-9 Flam. Liq. 3 Acute Tox. 4 * Aquatic Acute 1 … 46 unchanged lines … H411 GHS08 GHS09 Wng H373** H411 029-015-00-0 copper thiocyanate 214-183-1 1111-67-7 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 EUH032 M = 10 029-016-00-6 copper(II) oxide 215-269-1 1317-38-0 Aquatic Acute 1 H411 029-015-00-0 copper thiocyanate 214-183-1 1111-67-7 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 100 029-017-00-1 dicopper chloride trihydroxide 215-572-9 1332-65-6 Acute Tox. 4 Wng H410 EUH032 M = 10 M = 10 029-016-00-6 copper(II) oxide 215-269-1 1317-38-0 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 100 M = 10 029-017-00-1 dicopper chloride trihydroxide 215-572-9 1332-65-6 Acute Tox. 4 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 H332 H301 H400 H410 GHS06 GHS09 Dgr H332 H301 H410 M = 10 029-018-00-7 tetracopper hexahydroxide sulphate; [1] H410 inhalation: ATE = 2,83 mg/l (dusts or mists) oral: ATE = 299 mg/kg bw M = 10 M = 10 029-018-00-7 tetracopper hexahydroxide sulphate; [1] tetracopper hexahydroxide sulphate hydrate [2] 215-582-3 [1] 215-582-3 [2] 1333-22-8 [1] 12527-76-3 [2] Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410 M = 10 029-019-01-X copper flakes (coated with aliphatic acid) — — Acute Tox. 3 H410 oral: ATE = 500 mg/kg bw M = 10 M = 10 029-019-01-X copper flakes (coated with aliphatic acid) — — Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 H302 H319 H400 H410 GHS06 GHS09 Dgr H331 H302 H319 H410 M = 10 029-020-00-8 copper(II) carbonate--copper(II) hydroxide (1:1) 235-113-6 12069-69-1 Acute Tox. 4 H410 inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10 029-020-00-8 copper(II) carbonate—copper(II) hydroxide (1:1) 235-113-6 12069-69-1 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H332 H302 H319 H400 H410 GHS07 GHS09 Wng H332 H302 H319 H410 M = 10 029-021-00-3 copper dihydroxide; H410 inhalation: ATE = 1,2 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10 029-021-00-3 copper dihydroxide; copper(II) hydroxide 243-815-9 20427-59-2 Acute Tox. 2 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H330 H302 H318 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H302 H318 H410 M = 10 029-022-00-9 bordeaux mixture; H410 inhalation: ATE = 0,47 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10 029-022-00-9 bordeaux mixture; reaction products of copper sulphate with calcium dihydroxide — 8011-63-0 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H332 H318 H400 H410 GHS07 GHS05 GHS09 Dgr H332 H318 H410 M = 10 029-023-00-4 copper sulphate pentahydrate 231-847-6 7758-99-8 Acute Tox. 4 H410 inhalation: ATE = 1,97 mg/l (dusts or mists) M = 10 M = 1 029-023-00-4 copper sulphate pentahydrate 231-847-6 7758-99-8 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H318 H400 H410 GHS07 GHS05 GHS09 Dgr H302 H318 H410 M = 10 029-024-00-X granulated copper; H410 oral: ATE = 481 mg/kg bw M = 10 M = 1 029-024-00-X granulated copper; [particle length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm] 231-159-6 7440-50-8 Aquatic Chronic 2 H411 GHS09 H411 029-025-00-5 bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O’)copper; bis(N-cyclohexyl-diazenium-dioxy)-copper; [Cu-HDO] 239-703-4 312600-89-8 … 2,366 unchanged lines … H411 GHS07 GHS09 Wng H332 H411 601-029-00-7 dipentene; limonene;[1] (R)-p-mentha-1,8-diene; d-limonene; [2] (S)-p-mentha-1,8-diene; l-limonene; [3] trans-1-methyl-4-(1-methylvinyl)cyclohexene; [4] (±)-1-methyl-4-(1-methylvinyl)cyclohexene [5] 205-341-0 [1] 227-813-5 [2] 227-815-6 [3] 229-977-3 [4] 231-732-0 [5] 138-86-3 [1] 5989-27-5 [2] 5989-54-8 [3] 6876-12-6 [4] 7705-14-8 [5] Flam. Liq. 3 H411 601-029-00-7 dipentene; limonene [1] (S)-p-mentha-1,8-diene; l-limonene [2] trans-1-methyl-4-(1-methylvinyl)cyclohexene; [3] (±)-1-methyl-4-(1-methylvinyl)cyclohexene [4] 205-341-0 [1] 227-815-6 [2] 229-977-3 [3] 231-732-0 [4] 138-86-3 [1] 5989-54-8 [2] 6876-12-6 [3] 7705-14-8 [4] Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 … 458 unchanged lines … Muta. 2 H350 H341 GHS08 Dgr H350 H341 Carc. 1B; H350: C ≥ 0,001 % 602-001-00-7 chloromethane; H341 Carc. 1B; H350: C ≥ 0,001 % 601-093-00-6 1,4-dimethylnaphthalene 209-335-9 571-58-4 Acute Tox. 4 Asp. Tox. 1 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 3 H302 H304 H319 H400 H412 GHS07 GHS08 GHS09 Dgr H302 H304 H319 H410 oral: ATE = 1300 mg/kg bw M = 1 601-094-00-1 1-isopropyl-4-methylbenzene; p-cymene 202-796-7 99-87-6 Flam. Liq. 3 Acute Tox. 3 Asp. Tox. 1 Aquatic Chronic 2 H226 H331 H304 H411 GHS02 GHS06 GHS08 GHS09 Dgr H226 H331 H304 H411 inhalation: ATE = 3 mg/l (vapours) 601-095-00-7 p-mentha-1,3-diene; 1-isopropyl-4-methylcyclohexa-1,3-diene; alpha-terpinene 202-795-1 99-86-5 Flam. Liq. 3 Acute Tox. 4 Skin Sens. 1 Asp. Tox. 1 Aquatic Chronic 2 H226 H302 H317 H304 H411 GHS02 GHS07 GHS08 GHS09 Dgr H226 H302 H317 H304 H411 oral: ATE = 1680 mg/kg bw 601-096-00-2 (R)-p-mentha-1,8-diene; d-limonene 227-813-5 5989-27-5 Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1B Asp. Tox. 1 Aquatic Acute 1 Aquatic Chronic 3 H226 H315 H317 H304 H400 H412 GHS02 GHS07 GHS08 GHS09 Dgr H226 H315 H317 H304 H410 M = 1 602-001-00-7 chloromethane; methyl chloride 200-817-4 74-87-3 Flam. Gas 1 Press. Gas Carc. 2 … 1,318 unchanged lines … Lact. H361 H362 GHS08 Wng H361 H362 603-001-00-X methanol 200-659-6 67-56-1 Flam. Liq. 2 H362 602-110-00-X tetrafluoroethylene 204-126-9 116-14-3 Carc. 1B H350 GHS08 Dgr H350 603-001-00-X methanol 200-659-6 67-56-1 Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * … 248 unchanged lines … H314 inhalation: ATE = 700ppm (gases) oral: ATE = 100 mg/kg bw U 603-024-00-5 1,4-dioxane 204-661-8 123-91-1 Flam. Liq. 2 Carc. 2 Eye Irrit. 2 STOT SE 3 H225 H351 H319 H335 GHS02 Carc. 1B STOT SE 3 Eye Irrit. 2 H225 H350 H335 H319 GHS02 GHS08 GHS07 Dgr H225 H351 H319 H335 EUH019 H350 H335 H319 EUH019 EUH066 D 603-025-00-0 tetrahydrofuran 203-726-8 109-99-9 Flam. Liq. 2 Carc. 2 … 472 unchanged lines … H315 H319 H317 H412 dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw 603-066-00-4 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide 203-437-7 106-87-6 Carc. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * H351 H412 dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw 603-066-00-4 7-oxa-3-oxiranylbicyclo[4.1.0]heptane; 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide 203-437-7 106-87-6 Carc. 1B Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 H350 H341 H360F H331 H311 H301 GHS06 GHS08 Dgr H351 H302 GHS08 GHS06 Dgr H350 H341 H360F H331 H311 H301 * 603-067-00-X phenyl glycidyl ether; 2,3-epoxypropyl phenyl ether;1,2-epoxy-3-phenoxypropane 204-557-2 122-60-1 Carc. 1B Muta. 2 H302 inhalation: ATE = 0,5 mg/l (dusts or mists) oral: ATE = 1847 mg/kg bw 603-067-00-X phenyl glycidyl ether; 2,3-epoxypropyl phenyl ether;1,2-epoxy-3-phenoxypropane 204-557-2 122-60-1 Carc. 1B Muta. 2 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Skin Sens. 1 … 199 unchanged lines … Wng H312 H319 603-096-00-8 2-(2-butoxyethoxy)ethanol; diethylene glycol monobutyl ether 203-961-6 112-34-5 Eye Irrit. 2 H319 GHS07 Wng H319 603-097-00-3 1,1’,1’-nitrilotripropan-2-ol; triisopropanolamine 204-528-4 122-20-3 Eye Irrit. 2 H319 GHS07 Wng H319 603-098-00-9 2-phenoxyethanol 204-589-7 122-99-6 Acute Tox. 4 * Eye Irrit. 2 H302 H319 GHS07 Wng H302 H319 603-099-00-4 3-(N-methyl-N-(4-methylamino-3-nitrophenyl)amino)propane-1,2-diol hydrochloride 403-440-5 93633-79-5 Acute Tox. 4 * Wng H319 603-098-00-9 2-phenoxyethanol 204-589-7 122-99-6 Acute Tox. 4 STOT SE 3 Eye Dam. 1 H302 H335 H318 GHS05 GHS07 Dgr H302 H335 H318 oral: ATE = 1394 mg/kg bw 603-099-00-4 3-(N-methyl-N-(4-methylamino-3-nitrophenyl)amino)propane-1,2-diol hydrochloride 403-440-5 93633-79-5 Acute Tox. 4 * Aquatic Chronic 3 H302 H412 GHS07 Wng H302 … 773 unchanged lines … 126-91-0 [3] Skin Sens. 1B H317 GHS07 Wng H317 603-236-00-8 ethanol, 2,2’-iminobis-, N-(C13-15-branched and linear alkyl) derivs. 308-208-6 97925-95-6 Repr. 1B H360D GHS08 Dgr H360D 603-237-00-3 ipconazole (ISO); (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol - 125225-28-7 (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol — 125225-28-7 115850-69-6 115937-89-8 Repr. 1B Acute Tox. 4 STOT RE 2 Aquatic Chronic 1 H360D H302 H373 (eyes, skin, liver) H410 GHS08 GHS07 GHS09 Dgr H360D H302 H373 (eyes, skin, liver) H410 oral: ATE = 500 mg/kg bw M = 100 603-238-00-9 bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme 205-594-7 143-24-8 Repr. 1B H360FD GHS08 Dgr H360FD 603-239-00-4 paclobutrazol (ISO); (2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol - 76738-62-0 Repr. 2 (2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol — 76738-62-0 Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 … 822 unchanged lines … 227-633-7 [3] 97-54-1 [1] 5932-68-3 [2] 5912-86-7 [3] Skin Sens. 1A H317 GHS07 Wng H317 Skin Sens. 1A; H317: C ≥ 0,01 % 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2 Wng H317 Skin Sens. 1A; H317: C ≥ 0,01 % 604-095-00-5 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol; [DBMC] 204-327-1 119-47-1 Repr. 1B H360F GHS08 Dgr H360F 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2 Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* Skin Corr. 1B Skin Sens. 1 H350 … 358 unchanged lines … Wng H226 H332 H319 606-004-00-4 4-methylpentan-2-one; isobutyl methyl ketone 203-550-1 108-10-1 Flam. Liq. 2 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 H225 Carc. 2 Acute Tox. 4 STOT SE 3 Eye Irrit. 2 H225 H351 H332 H319 H335 GHS02 H336 H319 GHS02 GHS07 GHS08 Dgr H225 H351 H332 H319 H335 EUH066 606-005-00-X 2,6-dimethylheptan-4-one; di-isobutyl ketone 203-620-1 108-83-8 Flam. Liq. 3 H336 H319 EUH066 inhalation: ATE = 11 mg/l (vapours) 606-005-00-X 2,6-dimethylheptan-4-one; di-isobutyl ketone 203-620-1 108-83-8 Flam. Liq. 3 STOT SE 3 H226 H335 GHS02 GHS07 … 789 unchanged lines … Wng H302 H317 H412 EUH066 606-151-00-4 anthraquinone 201-549-0 84-65-1 Carc. 1B H350 GHS08 Dgr H350 607-001-00-0 formic acid … % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05 Dgr H350 606-152-00-X (5-chloro-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxy-o-tolyl)methanone; pyriofenone — 688046-61-9 Carc. 2 Aquatic Chronic 1 H351 H410 GHS08 GHS09 Wng H351 H410 M = 1 607-001-00-0 formic acid … % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05 Dgr H314 Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; H314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤C < 10 % … 2,140 unchanged lines … Dgr H330 H300 H410 607-255-00-2 fluroxypyr (ISO);4-amino-3,5-dichloro-6-fluoro-2-pyridyloxyacetic acid — 69377-81-7 Aquatic Chronic 3 H412 — H412 607-256-00-8 azoxystrobin (ISO); methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate - 131860-33-8 Acute Tox. 3 methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate — 131860-33-8 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 H331 H400 … 838 unchanged lines … Aquatic Chronic 3 H318 H412 GHS05 Dgr H318 H412 607-421-00-4 cypermethrin cis/trans +/-40/60; (RS)-α-cyano-3-phenoxybenzyl (1RS,3RS;1RS,3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 257-842-9 52315-07-8 Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 H412 607-421-00-4 cypermethrin (ISO); α-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; cypermethrin cis/trans +/- 40/60 257-842-9 52315-07-8 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H332 H302 H335 H373 (nervous system) H400 H410 GHS07 GHS08 GHS09 Wng H332 H302 H335 H410 607-422-00-X α-cypermethrin (ISO); racemate comprising (R)-α-cyano-3-phenoxybenzyl (1S,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; (S)-α-cyano-3-phenoxybenzyl(1R, 3R)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 257-842-9 67375-30-8 Acute Tox. 3 * STOT RE 2 * STOT SE 3 H373 (nervous system) H410 oral; ATE = 500 mg/kg bw inhalation; ATE = 3,3 mg/l (dusts or mists) M = 100000 M = 100000 607-422-00-X α-cypermethrin (ISO); racemate comprising (R)-α-cyano-3-phenoxybenzyl (1S,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; (S)-α-cyano-3-phenoxybenzyl(1R, 3R)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 257-842-9 67375-30-8 Acute Tox. 3 * STOT RE 2 * STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 H301 H373** H335 H400 H410 GHS06 GHS08 GHS09 Dgr H301 H373** H335 H410 M=1000 607-423-00-5 esters of mecoprop and of mecoprop-P — — Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H317 H400 H410 GHS07 GHS09 Wng H302 H317 H410 A 607-424-00-0 trifloxystrobin (ISO); (E, E)-α-methoxyimino-{2-[[[[1-[3-(trifluoromethyl)phenyl]ethylidene]amino]oxy]methyl]benzeneacetic acid methyl ester — 141517-21-7 Skin Sens. 1 607-424-00-0 trifloxystrobin (ISO); methyl (E)-methoxyimino-{(E)-α-[1-(α,α,α-trifluoro-m-tolyl)ethylideneaminooxy]-o-tolyl}acetate — 141517-21-7 Lact. Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 Aquatic Chronic 1 H362 H317 H400 H410 GHS07 GHS09 Wng H317 H410 607-425-00-6 metalaxyl (ISO); methyl-N-(2,6-dimethylphenyl)-N-(methoxyacetyl)-DL-alaninate 260-979-7 57837-19-1 Acute Tox. 4 * Wng H362 H317 H410 M = 100 M = 10 607-425-00-6 metalaxyl (ISO); methyl-N-(2,6-dimethylphenyl)-N-(methoxyacetyl)-DL-alaninate 260-979-7 57837-19-1 Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 H302 H317 … 69 unchanged lines … H335 H315 H317 H410 607-434-00-5 mecoprop-P [1] and its salts; (R)-2-(4-chloro-2-methylphenoxy)propionic acid 240-539-0 16484-77-8 Acute Tox. 4 * H410 607-434-00-5 mecoprop-P (ISO) [1] and its salts; (R)-2-(4-chloro-2-methylphenoxy)propionic acid [1] and its salts 240-539-0 [1] 16484-77-8 [1] Acute Tox. 4 Eye Dam. 1 Aquatic Chronic 2 H302 Aquatic Acute 1 Aquatic Chronic 1 H302 H318 H411 GHS05 GHS07 H400 H410 GHS07 GHS05 GHS09 Dgr H302 H318 H411 607-435-00-0 2S-isopropyl-5R-methyl-1R-cyclohexyl 2,2-dihydroxyacetate 416-810-6 111969-64-3 STOT RE 2 * H410 oral: ATE = 431 mg/kg bw M = 10 M = 10 607-435-00-0 2S-isopropyl-5R-methyl-1R-cyclohexyl 2,2-dihydroxyacetate 416-810-6 111969-64-3 STOT RE 2 * Eye Dam. 1 Aquatic Chronic 2 H373 ** H318 H411 GHS08 … 1,569 unchanged lines … H317 inhalation: ATE = 3 mg/L (dusts or mists) oral: ATE = 1100 mg/kg bw 8 9 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 607-747-00-7 2,2-dibromo-2-cyanoacetamide; [DBNPA] 233-539-7 10222-01-2 Acute Tox. 2 Acute Tox. 3 STOT RE 1 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H330 H301 H372 (respiratory tract) (inhalation) H315 H318 H317 H400 H410 GHS06 GHS08 GHS05 GHS09 Dgr H330 H301 H372 (respiratory tract) (inhalation) H315 H318 H317 H410 inhalation: ATE = 0,24 mg/l (dusts or mists) oral: ATE = 118 mg/kg bw M = 1 M = 1 607-748-00-2 [S-(Z,E)]-5-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)-3-methylpenta-2,4-dienoic acid; S-abscisic acid 244-319-5 21293-29-8 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 1 607-749-00-8 methyl salicylate 204-317-7 119-36-8 Repr. 2 Acute Tox. 4 Skin Sens. 1B Aquatic Chronic 3 H361d H302 H317 H412 GHS07 GHS08 Wng H361d H302 H317 H412 oral: ATE = 890 mg/kg bw 607-750-00-3 citric acid 201-069-1 77-92-9 Eye Irrit. 2 STOT SE 3 H319 H335 GHS07 Wng H319 H335 607-751-00-9 ethametsulfuron-methyl (ISO); methyl 2-({[4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)benzoate — 97780-06-8 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H319 H400 H410 GHS07 GHS09 Wng H319 H410 M = 1000 M = 100 607-752-00-4 trinexapac-ethyl (ISO); ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate — 95266-40-3 STOT RE 2 Skin Sens. 1B Aquatic Chronic 1 H373 (gastrointestinal tract) H317 H410 GHS08 GHS07 GHS09 Wng H373 (gastrointestinal tract) H317 H410 M = 1 607-753-00-X (3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide — 78821-43-9 Aquatic Chronic 4 H413 H413 607-754-00-5 benzyl salicylate 204-262-9 118-58-1 Skin Sens. 1B H317 GHS07 Wng H317 607-755-00-0 (RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate; tolpyralate — 1101132-67-5 Carc. 2 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H361fd H373 (eye) H400 H410 GHS08 GHS09 Wng H351 H361fd H373 (eye) H410 M = 10 M = 100 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 H225 H332 … 429 unchanged lines … Dgr H302 H318 H317 608-058-00-4 esfenvalerate (ISO); (S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate — 66230-04-4 Acute Tox. 3 * Acute Tox. 3 * (S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate — 66230-04-4 Acute Tox. 3 Acute Tox. 3 STOT SE 1 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H331 H301 H370 (nervous system) H373 H317 H400 H410 GHS06 GHS08 GHS09 Dgr H331 H301 H370 (nervous system) H373 H317 H410 M = 10000 608-059-00-X 5-amino-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-1H-pyrazole-3-carbonitrile 421-240-6 120068-79-3 Aquatic Chronic 2 H411 GHS09 H411 608-060-00-5 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile 421-300-1 138564-59-7 Aquatic Acute 1 H410 oral; ATE = 88,5 mg/kg bw inhalation; ATE = 0,53 mg/l (dusts or mists) M = 10000 M = 10000 608-059-00-X 5-amino-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-1H-pyrazole-3-carbonitrile 421-240-6 120068-79-3 Aquatic Chronic 2 H411 GHS09 H411 608-060-00-5 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile 421-300-1 138564-59-7 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 608-062-00-6 2-fluoro-4-hydroxybenzonitrile 422-810-7 82380-18-5 Acute Tox. 4 * … 984 unchanged lines … GHS09 Wng H302 H411 609-064-00-X mesotrione (ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione - 104206-82-8 Repr. 2 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione — 104206-82-8 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361d … 1,084 unchanged lines … H317 611-180-00-0 iron, complexes with diazotised 4-aminobenzenesulfonamide, diazotized 3-aminobenzenesulfonic acid, diazotised 3-amino-4-hydroxybenzenesulfonamide, diazotised 3-amino-4-hydroxy-N-phenylbenzenesulfonamide, diazotised 5-amino-2-(phenylamino)benzenesulfonic acid and resorcinol, sodium salts 417-850-7 — Aquatic Chronic 2 H411 GHS09 H411 611-181-00-6 potassium (oxido-NNO-azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO] - 66603-10-9 Flam. Sol. 1 [K-HDO] — 66603-10-9 Flam. Sol. 1 Acute Tox. 3 STOT RE 2 Skin Irrit. 2 … 1,016 unchanged lines … GHS09 Dgr H302 H314 H410 612-067-00-9 3-aminomethyl-3,5,5-trimethylcyclohexylamine 220-666-8 2855-13-2 Acute Tox. 4 * Acute Tox. 4 * H410 612-067-00-9 3-aminomethyl-3,5,5-trimethylcyclohexylamine 220-666-8 2855-13-2 Acute Tox. 4 Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 H312 H302 Eye Dam. 1 Skin Sens. 1A H302 H314 H317 H412 GHS05 H318 H317 GHS05 GHS07 Dgr H312 H302 Dgr H302 H314 H317 H412 612-068-00-4 3,3'-dichlorobenzidine; H317 oral: ATE = 1030 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,001 % 612-068-00-4 3,3'-dichlorobenzidine; 3,3'-dichlorobiphenyl-4,4'-ylenediamine 202-109-0 91-94-1 Carc. 1B Acute Tox. 4 * Skin Sens. 1 … 2,143 unchanged lines … H315 H317 H411 612-252-00-4 imidacloprid (ISO); 1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine 428-040-8 138261-41-3 Acute Tox. 4 * (E)-1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylideneamine; (2E)-1-[(6-chloropyridin-3-yl) methyl]-N-nitroimidazolidin-2-imine 428-040-8 138261-41-3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 H302 Aquatic Chronic 1 H301 H400 H410 GHS07 H410 GHS06 GHS09 Wng H302 H410 612-253-00-X 7-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one; [containing < 0,5 % formamide (EC No 200-842-0)] 429-400-7 199327-61-2 Aquatic Chronic 3 H412 — H412 612-253-01-7 7-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one; [containing ≥ 0,5 % formamide (EC No 200-842-0)] 429-400-7 199327-61-2 Repr. 1B Dgr H301 H410 oral: ATE = 131 mg/kg bw M = 100 M = 1000 612-253-00-X 7-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one; [containing < 0,5 % formamide (EC No 200-842-0)] 429-400-7 199327-61-2 Aquatic Chronic 3 H412 — H412 612-253-01-7 7-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one; [containing ≥ 0,5 % formamide (EC No 200-842-0)] 429-400-7 199327-61-2 Repr. 1B Aquatic Chronic 3 H360D*** H412 GHS08 Dgr H360D*** … 357 unchanged lines … H411 EUH071 8 9 612-292-00-2 methylhydrazine 200-471-4 60-34-4 Carc. 1B H350 GHS08 Dgr H350 612-293-00-8 reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine 447-920-2 - Repr. 2 Dgr H350 612-293-00-8 reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine 447-920-2 — Repr. 2 Acute Tox. 4 Skin Corr. 1B Eye Dam. 1 H361f … 538 unchanged lines … GHS09 Dgr H301 H312 H410 613-048-00-8 carbendazim (ISO);methyl benzimidazol-2-ylcarbamate 234-232-0 10605-21-7 Muta. 1B Repr. 1B H410 613-048-00-8 carbendazim (ISO); methyl benzimidazol-2-ylcarbamate 234-232-0 10605-21-7 Muta. 1B Repr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H340 H360FD H400 H410 GHS08 H360FD H317 H400 H410 GHS07 GHS08 GHS09 Dgr H340 H360FD H410 613-049-00-3 benomyl (ISO);methyl 1-(butylcarbamoyl)benzimidazol-2-ylcarbamate 241-775-7 17804-35-2 Muta. 1B Repr. 1B STOT SE 3 H360FD H317 H410 M = 10 M = 10 613-049-00-3 benomyl (ISO);methyl 1-(butylcarbamoyl)benzimidazol-2-ylcarbamate 241-775-7 17804-35-2 Muta. 1B Repr. 1B STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 … 462 unchanged lines … Aquatic Chronic 3 H317 H412 GHS07 Wng H317 H412 613-102-00-0 dimethomorph (ISO);4-(3-(4-chlorophenyl)-3-(3,4- dimethoxyphenyl)acryloyl)morpholine 404-200-2 110488-70-5 Aquatic Chronic 2 H411 GHS09 H411 613-103-00-6 sodium 5-n-butylbenzotriazole 404-450-2 118685-34-0 Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 H412 613-102-00-0 dimethomorph (ISO); (E,Z)-4-(3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acryloyl)morpholine 404-200-2 110488-70-5 Repr. 1B Aquatic Chronic 2 H360F H411 GHS08 GHS09 Dgr H360F H411 613-103-00-6 sodium 5-n-butylbenzotriazole 404-450-2 118685-34-0 Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 H302 H314 H317 … 41 unchanged lines … H411 GHS07 GHS09 Wng H302 H411 613-111-00-X 1,2,4-triazole 206-022-9 288-88-0 Repr. 2 Acute Tox. 4 * Eye Irrit. 2 H361d *** H302 H411 613-111-00-X 1,2,4-triazole 206-022-9 288-88-0 Repr. 1B Acute Tox. 4 Eye Irrit. 2 H360FD H302 H319 GHS08 GHS07 Wng H361d *** H302 H319 613-112-00-5 octhilinone (ISO); Dgr H360FD H302 H319 oral: ATE = 1320 mg/kg bw 613-112-00-5 octhilinone (ISO); 2-octyl-2H-isothiazol-3-one; [OIT] 247-761-7 26530-20-1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 … 143 unchanged lines … Wng H361d *** H302 H315 H411 613-125-00-6 hexythiazox (ISO); trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide - 78587-05-0 Aquatic Acute 1 trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide — 78587-05-0 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 … 209 unchanged lines … Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M=100 613-166-00-X flumioxazin (ISO); 2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione — 103361-09-7 Repr. 1B N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboximide — 103361-09-7 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 H360D Aquatic Chronic 1 H361d H400 H410 GHS08 GHS09 Dgr H360D Wng H361d H410 M = 1000 M = 1000 613-167-00-5 reaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1) — 55965-84-9 Acute Tox. 2 Acute Tox. 2 … 326 unchanged lines … H302 H317 H410 EUH070 613-202-00-4 pymetrozine (ISO); (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one - 123312-89-0 Carc. 2 (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one — 123312-89-0 Carc. 2 Repr. 2 Aquatic Chronic 1 H351 H361fd … 37 unchanged lines … Aquatic Chronic 1 H400 H410 GHS09 Wng H410 613-208-00-7 imazamox (ISO); (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid — 114311-32-9 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 613-209-00-2 cis-1-(3-chloropropyl)-2,6-dimethyl-piperidin hydrochloride 417-430-3 63645-17-0 Acute Tox. 3 * (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid — 114311-32-9 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 H361d H400 H410 GHS08 GHS09 Wng H361d H410 M = 10 M = 10 613-209-00-2 cis-1-(3-chloropropyl)-2,6-dimethyl-piperidin hydrochloride 417-430-3 63645-17-0 Acute Tox. 3 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 H301 … 335 unchanged lines … H302 H317 H411 613-267-00-9 thiamethoxam (ISO); 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine 428-650-4 153719-23-4 Acute Tox. 4 * 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine 428-650-4 153719-23-4 Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 Aquatic Chronic 1 H361fd H302 H400 H410 GHS07 GHS08 GHS09 Wng H302 H410 M=10 613-268-00-4 (4aS-cis-)-6-benzyl-octahydropyrrolo[3.4-b]pyridine 425-930-8 151213-39-7 Skin Corr. 1B Wng H361fd H302 H410 oral: ATE = 780 mg/kg bw M = 10 M = 10 613-268-00-4 (4aS-cis-)-6-benzyl-octahydropyrrolo[3.4-b]pyridine 425-930-8 151213-39-7 Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * … 122 unchanged lines … H319 H315 H411 613-282-00-0 triticonazole (ISO); (RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol — 131983-72-7 Aquatic Chronic 2 H411 GHS09 H411 613-283-00-6 ketoconazole; (RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol — 138182-18-0 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361f H373 H400 H410 GHS08 GHS09 Wng H361f H373 H410 M = 1 M = 1 613-283-00-6 ketoconazole; 1-[4-[4-[[(2SR, 4RS)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone 265-667-4 65277-42-1 Repr. 1B Acute Tox. 3 * STOT RE 2 * … 379 unchanged lines … H410 M = 1000 M = 1000 613-330-00-0 2-methylimidazole 211-765-7 693-98-1 Repr. 1B H360Df GHS08 Dgr H360Df 613-331-00-6 (2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol; mefentrifluconazole - 1417782-03-6 Skin Sens. 1 mefentrifluconazole — 1417782-03-6 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410 M = 1 M = 1 613-332-00-1 oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone - 1003318-67-9 Aquatic Chronic 1 H410 GHS09 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone — 1003318-67-9 Aquatic Chronic 1 H410 GHS09 Wng H410 M = 1 613-333-00-7 pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyridine-2(1H)-thionato-.kappa.S]zinc 236-671-3 13463-41-7 Repr. 1B Acute Tox. 2 Acute Tox. 3 … 61 unchanged lines … Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100 613-336-00-3 2-methyl-1,2-benzothiazol-3(2H)-one; [MBIT] - 2527-66-4 Acute Tox. 4 [MBIT] — 2527-66-4 Acute Tox. 4 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 … 15 unchanged lines … H410 EUH071 dermal: ATE = 1100 mg/kg bw oral: ATE = 175 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 1 614-001-00-4 nicotine (ISO); M = 1 613-337-00-9 prothioconazole (ISO); 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione — 178928-70-6 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 10 M = 1 613-338-00-4 azamethiphos (ISO); S-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl] O,O-dimethyl thiophosphate 252-626-0 35575-96-3 Carc. 2 Acute Tox. 3 Acute Tox. 4 STOT SE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H331 H302 H370 (nervous system) H317 H400 H410 GHS06 GHS08 GHS09 Dgr H351 H331 H302 H370 (nervous system) H317 H410 inhalation: ATE = 0,5 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 1000 M = 1000 613-339-00-X 3-methylpyrazole 215-925-7 1453-58-3 Repr. 1B Acute Tox. 4 STOT RE 2 Skin Corr. 1 Eye Dam. 1 H360D H302 H373 (lung) H314 H318 GHS08 GHS07 GHS05 Dgr H360D H302 H373 (lung) H314 oral: ATE = 500 mg/kg bw 613-340-00-5 clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one — 81777-89-1 Acute Tox. 4 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H332 H302 H400 H410 GHS07 GHS09 Wng H332 H302 H410 inhalation: ATE = 4,85 mg/l (dusts or mists) oral: ATE = 768 mg/kg bw M = 1 M = 1 614-001-00-4 nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 … 171 unchanged lines … Dgr H318 614-029-00-7 constitutional isomers of penta-O-allyl-β-D-fructofuranosyl-α-D-glucopyranoside; constitutional isomers of hexa-O-allyl-β-D-fructofuranosyl-α-D-glucopyranoside; constitutional isomers of hepta-O-allyl-β-D-fructofuransoyl-α-D-glucopyranoside 419-640-0 68784-14-5 Acute Tox. 4 * H302 GHS07 Wng H302 615-001-00-7 methyl isocyanate 210-866-3 624-83-9 Flam. Liq. 2 Wng H302 614-030-00-2 emamectin benzoate (ISO); (4"R)-4"-deoxy-4"-(methylamino) avermectin B1 benzoate — 155569-91-8 Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 STOT SE 1 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H331 H311 H301 H370 (nervous system) H372 (nervous system) H318 H400 H410 GHS06 GHS05 GHS08 GHS09 Dgr H331 H311 H301 H370 (nervous system) H372 (nervous system) H318 H410 inhalation: ATE = 0,663 mg/l (dusts or mists) dermal: ATE = 300 mg/kg bw oral: ATE = 60 mg/kg bw STOT RE 1; H372: C ≥ 5 %; STOT RE 2; H373: 0,5 % ≤ C < 5 % M = 10000 M = 10000 615-001-00-7 methyl isocyanate 210-866-3 624-83-9 Flam. Liq. 2 Repr. 2 Acute Tox. 2 * Acute Tox. 3 * … 782 unchanged lines … Wng H302 H317 H410 616-032-00-9 diflufenican (ISO); N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide — 83164-33-4 Aquatic Chronic 3 H412 — H412 616-033-00-4 cyprofuram (ISO); N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide; 2′,4′-difluoro-2-(α,α,α-trifluoro-m-tolyloxy) nicotinanilide — 83164-33-4 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 10000 M = 1000 616-033-00-4 cyprofuram (ISO); N-(3-chlorophenyl)-N-(tetrahydro-2-oxo-3-furyl)cyclopropanecarboxamide 274-050-9 69581-33-5 Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 … 331 unchanged lines … H410 GHS08 GHS09 Wng H351 H361d *** H410 616-106-00-0 phenmedipham (ISO); methyl 3-(3-methylcarbaniloyloxy)carbanilate 237-199-0 13684-63-4 Aquatic Acute 1 H361d *** H410 616-106-00-0 phenmedipham (ISO); methyl 3-(3-methylcarbaniloyloxy)carbanilate 237-199-0 13684-63-4 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 616-107-00-6 cinidon ethyl (ISO); Wng H410 M = 10 M = 10 616-107-00-6 cinidon ethyl (ISO); ethyl (Z)-2-chloro-3-[2-chloro-5-(cyclohex-1-ene-1,2-dicarboximido)phenyl]acrylate — 142891-20-1 Carc. 2 Skin Sens. 1 Aquatic Acute 1 … 27 unchanged lines … GHS09 Wng H373 ** H410 616-113-00-9 desmedipham (ISO); ethyl 3-phenylcarbamoyloxyphenylcarbamate 237-198-5 13684-56-5 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M=10 616-114-00-4 dodecanamide, N,N'-(9,9',10,10'-tetrahydro-9,9',10,10'-tetraoxo(1,1'-bianthracene)-4,4'-diyl)bis- 418-010-2 136897-58-0 Aquatic Chronic 4 H413 — H413 616-115-00-X N-(3-acetyl-2-hydroxyphenyl)-4-(4-phenylbutoxy)benzamide 416-150-9 136450-06-1 Aquatic Chronic 4 H413 — H413 616-116-00-5 N-(4-dimethylaminopyridinium)-3-methoxy-4-(1-methyl-5-nitroindol-3-ylmethyl)-N-(o-tolylsulfonyl)benzamidate 416-790-9 143052-96-4 Aquatic Chronic 4 H413 — H413 616-117-00-0 N-[2-(3-acetyl-5-nitrothiophen-2-ylazo)-5-diethylaminophenyl]acetamide 416-860-9 777891-21-1 Repr. 2 ethyl 3-phenylcarbamoyloxyphenylcarbamate 237-198-5 13684-56-5 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 H361d H400 H410 GHS08 GHS09 Wng H361d H410 M = 10 M = 10 616-114-00-4 dodecanamide, N,N'-(9,9',10,10'-tetrahydro-9,9',10,10'-tetraoxo(1,1'-bianthracene)-4,4'-diyl)bis- 418-010-2 136897-58-0 Aquatic Chronic 4 H413 — H413 616-115-00-X N-(3-acetyl-2-hydroxyphenyl)-4-(4-phenylbutoxy)benzamide 416-150-9 136450-06-1 Aquatic Chronic 4 H413 — H413 616-116-00-5 N-(4-dimethylaminopyridinium)-3-methoxy-4-(1-methyl-5-nitroindol-3-ylmethyl)-N-(o-tolylsulfonyl)benzamidate 416-790-9 143052-96-4 Aquatic Chronic 4 H413 — H413 616-117-00-0 N-[2-(3-acetyl-5-nitrothiophen-2-ylazo)-5-diethylaminophenyl]acetamide 416-860-9 777891-21-1 Repr. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H361f *** H317 … 547 unchanged lines … Wng H361fd H362 H373 616-228-00-4 3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad - 907204-31-3 Lact. fluxapyroxad — 907204-31-3 Lact. Aquatic Acute 1 Aquatic Chronic 1 H362 H400 H410 GHS09 Wng H362 H410 M = 1 M = 1 616-230-00-5 N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA] 213-103-2 924-42-5 Carc. 1B Muta. 1B STOT RE 1 H350 H340 H372 (peripheral nervous system) GHS08 Dgr H350 H340 H372 (peripheral nervous system) 616-231-00-0 5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazole-4-carboxamide; 2'-[(RS)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen - 494793-67-8 Carc. 2 penflufen — 494793-67-8 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410 M = 1 M = 1 616-232-00-6 iprovalicarb (ISO); isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate - 140923-17-7 Carc. 2 H351 GHS08 isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate — 140923-17-7 Carc. 2 H351 GHS08 Wng H351 616-233-00-1 silthiofam (ISO); N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide - 175217-20-6 STOT RE 2 N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide — 175217-20-6 STOT RE 2 Aquatic Chronic 2 H373 H411 GHS08 GHS09 Wng H373 H411 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 H411 616-234-00-7 N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen — 1228284-64-7 Carc. 2 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H361f H400 H410 GHS08 GHS09 Wng H351 H361f H410 M = 1 M = 1 616-235-00-2 N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane — 874967-67-6 Carc. 2 Aquatic Acute 1 Aquatic Chronic 2 H351 H400 H411 GHS08 GHS09 Wng H351 H410 M = 1 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 H225 H341 GHS02 GHS08 … 24,961 unchanged lines … S: 61 650-055-00-5 silver sodium zirconium hydrogenphosphate 422-570-3 155925-27-2 N; R50-53 N R: 50/53 S: 60-61